Paronychia is a rare complication of pemphigus vulgaris (PV), and the immunological profile of patients with digital disease has not been assessed so far. We report 2 cases of PV with oral mucosa and periungual involvement, who had high titers of anti- desmoglein (Dsg)-3 circulating antibodies. These observations raise the possibility that expression of Dsg-1 and Dsg-3 in distinct areas of periungual skin is disease specific and that anti-Dsg-3 antibodies alone may have an as yet unrecognized importance for the development of paronychia in PV.

Keywords:
Anti-desmoglein-1 and -3 antibodies, Pemphigus, Pemphigus antibodies
1.
Schlesinger N, Katz M, Ingber A: Nail involvement in pemphigus vulgaris. Br J Dermatol 2002;146:836–839.
2.
Engineer L, Norton LA, Ahmed AR: Nail involvement in pemphigus vulgaris. J Am Acad Dermatol 2000;43:529–535.
3.
Kolivras A, Gheeraert P, Andre J: Nail destruction in pemphigus vulgaris. Dermatology 2003;206:351–352.
4.
Lee HE, Wong WR, Lee MC, Hong HS: Acute paronychia heralding the exacerbation of pemphigus vulgaris. Int J Clin Pract 2004;58:1174–1176.
5.
Lieb J, Levitt J, Sapadin AN: Nail findings in pemphigus vulgaris. Int J Dermatol 2006;45:172–174.
6.
Tan HH, Tay YK: An unusual case of pemphigus vulgaris presenting as bilateral foot ulcers. Clin Exp Dermatol 2000;25:224–226.
7.
Torok L, Husz S, Ocsai H, Krischner A, Kiss M: Pemphigus vegetans presenting as acrodermatitis continua suppurativa. Eur J Dermatol 2003;13:579–581.
8.
Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T: The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999;40:167–170.
9.
Nagasaka A, Matsue H, Miyahara A, Shimada S: Pemphigus vulgaris with no mucosal lesions showing pemphigus-foliaceus-like skin manifestations: is there a ‘cutaneous type’ of pemphigus vulgaris? Dermatology 2005;211:372–374.
10.
Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR: Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999;103:461–468.
11.
Baykal C, Azizlerli G, Thoma-Uszynski S, Hertl M: Pemphigus vulgaris localized to the nose and cheeks. J Am Acad Dermatol 2002;47:875–880.
12.
Milingou M, Wood P, Masouyé I, McLean WH, Borradori L: Focal palmoplantar keratoderma caused by an autosomal dominant inherited mutation in the desmoglein 1 gene. Dermatology 2006;212:117–122.
13.
Koch PJ, Mahoney MG, Ishikawa H, Pulkkinen L, Uitto J, Shultz L, et al: Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 1997;137:1091–1102.
14.
Nishifuji K, Olivry T, Ishii K, Iwasaki T, Amagai M: IgG autoantibodies directed against desmoglein 3 cause dissociation of keratinocytes in canine pemphigus vulgaris and paraneoplastic pemphigus. Vet Immunol Immunopathol 2007;117:209–221.
15.
Bolling MC, Mekkes JR, Goldschmidt WF, van Noesel CJ, Jonkman MF, Pas HH: Acquired palmoplantar keratoderma and immunobullous disease associated with antibodies to desmocollin 3. Br J Dermatol 2007;157:168–173.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.